Sanofi CEO courts controversy after saying US is first in li...

Sanofi’s CEO Paul Hudson has courted controversy by saying the French pharma’s potential COVID-19 vaccine will likely be delivered to the US government first should it succeed in clinical t

Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark

Sanofi and Regeneron eye challenge to Merck & Co in first li...

Sanofi and Regeneron could mount a challenge to Merck & Co’s Keytruda in untreated advanced lung cancer with their cancer immunotherapy latecomer Libtayo following new phase 3 results. 

Jury still out on IL-6 drugs in COVID-19 following prelimina...

There is a growing body of evidence that already-approved IL-6 could be used as treatments for COVID-19 following newly published clinical trial data – but the jury is out on whether they c

Sanofi links with Luminostics on smartphone coronavirus test

Sanofi and GSK join forces on coronavirus vaccine

As the world waits with bated breath for a coronavirus vaccine, two of the world’s biggest vaccine manufacturers, Sanofi and GSK, have announced they are teaming up to develop an adjuvanted cand